ALPM.Y Stock Overview
Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥10.14 |
| 52 Week High | JP¥13.14 |
| 52 Week Low | JP¥9.15 |
| Beta | 0.22 |
| 11 Month Change | -10.58% |
| 3 Month Change | -19.40% |
| 1 Year Change | -17.29% |
| 33 Year Change | -37.21% |
| 5 Year Change | -40.91% |
| Change since IPO | 37.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALPM.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.8% | 2.8% | 2.2% |
| 1Y | -17.3% | 11.8% | 32.6% |
Return vs Industry: ALPM.Y underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: ALPM.Y underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| ALPM.Y volatility | |
|---|---|
| ALPM.Y Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALPM.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALPM.Y's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 14,754 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| ALPM.Y fundamental statistics | |
|---|---|
| Market cap | US$18.26b |
| Earnings (TTM) | US$355.16m |
| Revenue (TTM) | US$11.50b |
51.4x
P/E Ratio1.6x
P/S RatioIs ALPM.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPM.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥1.77t |
| Cost of Revenue | JP¥322.95b |
| Gross Profit | JP¥1.45t |
| Other Expenses | JP¥1.39t |
| Earnings | JP¥54.75b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 30.58 |
| Gross Margin | 81.78% |
| Net Profit Margin | 3.09% |
| Debt/Equity Ratio | 61.2% |
How did ALPM.Y perform over the long term?
See historical performance and comparison